Abeona Therapeutics(US:ABEO) Globenewswire·2025-05-14 11:30Core Insights - ZEVASKYN is the first and only cell-based gene therapy approved for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) [2][8] - Ann & Robert H. Lurie Children's Hospital of Chicago is the first Qualified Treatment Center (QTC) for ZEVASKYN, ready to begin patient evaluations [1][3] - Abeona Therapeutics has established the Abeona Assist™ program to provide personalized support for patients and families throughout the treatment process [5] Company Overview - Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, with ZEVASKYN being a key product [15] - The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio, which is responsible for the commercial production of ZEVASKYN [15] - Abeona is committed to enabling access to ZEVASKYN for eligible patients in the U.S. through comprehensive support services [5] Treatment Details - ZEVASKYN is indicated for the treatment of wounds in both adult and pediatric patients with RDEB, utilizing gene-modified cellular sheets to promote healing [9][8] - The therapy incorporates the COL7A1 gene into a patient's skin cells to produce functional type VII collagen, which is essential for skin integrity [8][7] - Clinical data has shown that ZEVASKYN can lead to meaningful wound healing and pain reduction with a single application [8] Hospital Collaboration - Lurie Children's Hospital has been recognized for its expertise in treating epidermolysis bullosa and has been a center for excellence in genetic skin diseases for over 30 years [3][12] - The hospital has been providing FDA-approved gene therapies since 2019 and is expanding its offerings, with ZEVASKYN being the tenth gene therapy available [4] - The first patient is expected to receive ZEVASKYN treatment in August 2025, following biopsies in July 2025 [4]